This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6(3):267–74.
Hill ME, Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev 1998;24(2):113–18.
Douglass HO, Jr, Lavin PT, Goudsmit A et al. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2(12):1372–81.
Wils JA, Klein HO, Wagener DJ et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin — a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9(5):827–31.
Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18(14):2648–57.
Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5(7):609–16.
Ross P, Nicolson M, Cunningham D et al. A prospective randomised trial comparing MCF with ECF in advanced oesophago-gastric cancer. Submitted 2001.
Pozzo C, Bugat R, Peschel C et al. Irinotecan in combination with CDDP or 5FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: Final results of a randomised phase II study. Proc Am Soc Clin Oncol 2001;20(abstr).
Van Cutsem E, Ayani J, Tjulandin S et al. Docetaxel in combination with cisplatinum with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma: Preliminary results. Ann Oncol 2001;11(S4)(abstr).
Fielding J, Scholefield J, Stuart R et al. A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 2000;19(abstr).
Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000;11(7):837–43.
Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15(1):261–7.
Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114(2):205–9.
Ando N, Iizuka T, Kakegawa T et al. A randomized trial comparing surgery to surgery plus postoperative chemotherapy for localised squamous cell carcinoma of the thoracic esophagus. Proc Am Soc Clin Oncol 1998;17. (abstr).
Macdonald JS, Smalley S, Benedetti J et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol 2000; 19 (abstr).
Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229(3):303–8.
Clark P. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomised controlled trial conducted by the UK Medical Research Council Upper GI tract cancer group. Proc Am Soc Clin Oncol 2001;20(abstr).
Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339(27):1979–84.
Herskovic A, Martz K, al Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593–8.
Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462–7.
Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19(2):305–13.
Flamen P, Lerut A, Van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18(18):3202–10.
Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16(1):309–16.
Rights and permissions
Copyright information
© 2005 Springer-Verlag London Limited
About this chapter
Cite this chapter
Tebbutt, N.C., Cunningham, D. (2005). Chemotherapy of Upper GI Neoplasms: Proven/Unproven. In: Upper Gastrointestinal Surgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/1-84628-066-4_26
Download citation
DOI: https://doi.org/10.1007/1-84628-066-4_26
Publisher Name: Springer, London
Print ISBN: 978-1-85233-607-3
Online ISBN: 978-1-84628-066-5
eBook Packages: MedicineMedicine (R0)